Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
Loading...
Date
Authors
Zweegman, S.
Stege, C.A.M.
Haukas, E.
Schjesvold, F.H.
Levin, M.D.
Waage, A.
Leys, R.B.L.
Klein, S.K.
Szatkowski, D.
Axelsson, P.